Application 761088

Type
BLA
Sponsor
CELLTRION INC

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001TRUXIMARITUXIMAB-ABBSINJECTABLE;INJECTION100MG/10ML(10MG/ML)NoNo
002TRUXIMARITUXIMAB-ABBSINJECTABLE;INJECTION500MG/50ML(10MG/ML)NoNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
63459-103Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-103Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-103Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-103Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-103Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-103Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-103Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-103Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-104Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-104Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-104Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-104Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-104Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-104Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-104Truximarituximab-abbsCephalon, Inc.BLACurrent
63459-104Truximarituximab-abbsCephalon, Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
83235SUPPL 2025-08-29
82512SUPPL 2025-06-10
70122SUPPL2022-02-08
70121SUPPL2022-02-08
70113SUPPL2022-02-08
63394SUPPL2020-06-02
63393SUPPL2020-06-02
63389SUPPL2020-06-02
61404SUPPL2019-12-23
61403SUPPL2019-12-23
61357SUPPL2019-12-19
61356SUPPL2019-12-19
61355SUPPL2019-12-19
61354SUPPL2019-12-19
58858SUPPL2019-05-31
58857SUPPL2019-05-31
58849SUPPL2019-05-31
58848SUPPL2019-05-31
58847SUPPL2019-05-31
58846SUPPL2019-05-31
57811ORIG2019-02-26
57808ORIG2019-02-25
56580ORIG2018-11-28